1258428-71-5

Basic information

• Product Name: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone
• Synonyms: Montelukast Related Impuirty 1;1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone;(E)-1-(3-(2-(7-chloroquinolin-2-yl)vinyl)phenyl)-3-(2-(2-hydroxypropan-2-yl)phenyl)propan-1-one;Montelukast Sodium Impurity A
• CAS NO: 1258428-71-5
• Molecular Formula: C29H26ClNO2
• Molecular Weight: 455.97524
• EINECS: -0
• Product Categories: Chiral Reagents, Impurities, Pharmaceuticals, Intermediates & Fine Chemicals, Sulfur & Selenium Compounds
• Mol File: 1258428-71-5.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 651.5±55.0 °C(Predicted)
• Appearance: /
• Density: 1.237±0.06 g/cm3(Predicted)
• Storage Temp.: Amber Vial, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), DMSO (Slightly)
• PKA: 14.46±0.29(Predicted)
• CAS DataBase Reference: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone(CAS DataBase Reference)
• NIST Chemistry Reference: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone(1258428-71-5)
• EPA Substance Registry System: 1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone(1258428-71-5)

Safety Data

• Hazardous Substances Data: 1258428-71-5(Hazardous Substances Data)

Usage

Description

1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone is a complex organic compound with a unique chemical structure. It is an impurity found in Montelukast, a medication used for treating asthma.

Uses

1. Used in Pharmaceutical Industry:
1-[3-[(1E)-2-(7-Chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-Methylethyl)phenyl]-1-propanone is used as an impurity in Montelukast (M568000) for [application type] as an antiasthmatic. [application reason] It is a selective leukotriene D4-receptor antagonist that helps in managing asthma symptoms by blocking the action of leukotrienes, which are inflammatory mediators.

Upstream product

• 1208128-87-3 2-(2-ortho(2-bromoethyl)phenylpropyl)tetrahydropyran ether 
• 1208128-84-0 3-(2-(7-chloro-2-quinolyl)vinyl)benzonitrile 
• 1208128-85-1 2-(2-orthomethylphenylpropyl)tetrahydropyrane ether 
• 7572-79-4 2-(2-methylphenyl)propan-2-ol 
• 577-16-2 2-Methylacetophenone 
• 4965-33-7 2-methyl-7-chloroquinoline 
• 24964-64-5 3-Cyanobenzaldehyde 
• 177748-00-4 7-chloro-2-ethenylquinoline 
• 762272-97-9 1-(3-bromophenyl)-3-[2-(1-hydroxy-1-methylethyl)phenyl]propan-1-one 
• 762272-95-7 2-[3-(3-bromophenyl)-3-hydroxypropyl]benzoic acid methyl ester 
• 120578-03-2 (E)-3-[2-(7-chloro-2-quinolinyl)ethenyl]benzaldehyde 
• 7073-69-0 2-(2-bromophenyl)propanol 
• 149968-10-5 (E)-3-<2-(7-chloro-2-quinolinyl)ethenyl>-α-ethenylphenylmethanol 
• 610-94-6 2-bromobenzoic acid methyl ester 

Downstream Products

• 1359172-54-5 (S)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)-vinyl]-phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxy-ethyl)-phenyl]-propan-1-ol 
• 1359172-33-0 C₃₃H₃₈ClNO₄SSi 
• 1359172-36-3 (1-{(R)-1-{3-[(E)-2-(7-chloro-quinolin-2-yl)vinyl]phenyl}-3-[2-(1-methyl-1-trimethylsilanyloxyethyl)phenyl]propylsulfanylmethyl}cyclopropyl)acetic acid methyl ester 

Relevant articles and documents

An enantioselective formal synthesis of montelukast sodium

A formal synthesis of the antiasthma drug montelukast sodium is described, wherein the key chiral diol intermediate was accessed with greater convergence of the C-C bond-forming steps as compared to previous routes. Improved synthetic efficiency was achie

PREPARATION OF PRECURSORS FOR LEUKOTRIENE ANTAGONISTS

The present invention relates to an improved process for the preparation of a compound having formula (I). The compound having formula (I) is the backbone diol precursor/intermediate used to produce montelukast sodium. Montelukast sodium is a leukotriene

PROCESS FOR THE PREPARATION OF MONTELUKAST SODIUM

The present invention relates to a process for the synthesis of Montelukast sodium of formula I the chemical name of which is [(R)-(E)]-1-[[[1-[3-[2-(7-chloro-2- quinolinyl)ethenyl]phenyl] -3 - [2-( 1 -hydroxy- 1 -methylethyl)phenyl]propyl] thio]methyl] - -cyclopropaneacetic acid sodium salt. The present invention further provides compounds of general formulae V, VI, VIb and VIII as new intermediates.